Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
30.65
+0.80 (2.68%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Rapport Therapeutics Market Cap
Rapport Therapeutics has a market cap or net worth of $1.47 billion as of October 9, 2026. It is the 8,251st most valuable company in the world and the 2,001st biggest in the United States. Its market cap has increased by 17.85% in one year.
Market Cap
1.47B
Enterprise Value
1.04B
1-Year Change
17.85%
Global Rank
Country Rank
#2,001 United States
Category
ChartMarket Cap Chart
Since the IPO on June 7, 2024, Rapport Therapeutics's market cap has increased from $601.40M to $1.47B, an increase of 144.52%. That is a compound annual growth rate of 46.54%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 1.47B | 1.69% |
| Dec 31, 2025 | 1.45B | 122.86% |
| Dec 31, 2024 | 648.87M | 7.89% |
| Jun 7, 2024 | 601.40M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Innoviva | 1.53B |
| Ultragenyx Pharmaceutical | 1.52B |
| Syndax Pharmaceuticals | 1.52B |
| Immunocore Holdings | 1.51B |
| Maze Therapeutics | 1.51B |
| Kailera Therapeutics | 1.51B |
| Hemab Therapeutics Holdings | 1.48B |
| Taysha Gene Therapies | 1.46B |